Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of neoadjuvant treatment with
pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide +/- trastuzumab followed by
docetaxel in patients with locally advanced, inflammatory breast cancer or with a primary
tumor > 5 cm.
Phase:
Phase 2
Details
Lead Sponsor:
Herlev Hospital
Collaborators:
Aarhus University Hospital Odense University Hospital Rigshospitalet, Denmark